KBC Securities - Zealand Pharma A/S (ZLDPF) Zealand Pharma Completes petrelintide phase 2b enrolment in obesity/overweight

Report

KBC Securities

Jacob Mekhael

Zealand Pharma Completes petrelintide phase 2b enrolment in obesity/overweight

Zealand announced that the last participant has been enrolled and randomised in the phase 2b (ZUPREME-1) trial of petrelintide (long acting amylin analog, SC) in people with obesity or overweight with weight-related comorbidities. While the company has not provided specific guidance for when results will be released, we expect this to be around 1Q26 taking into account the 42 week treatment period. We reiterate our DKK 970 TP and BUY rating.

17/03/2025 1 EN

Underlying

Zealand Pharma A/S

Zealand Pharma is a biotechnology company. Co. is engaged in the discovery development and commercialization of peptide-based medicines. Co.'s pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.

See profile

DK0060257814 Pink OTC Markets United States

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Jacob Mekhael

Other Reports on these Companies

KBC Securities

Morning Notes : ZEAL DC

: ZEAL DC

March 17, 2025 March 17, 2025 1 EN

GlobeNewsWire

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Press release – No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phase 2b ZUPREME-1 trial is designed to evaluate five target doses of petrelintide up to 9 mg over 42 weeks of treatment.Zealand Pharma remains on track to initiate the Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabet...

March 17, 2025 March 17, 2025 1 EN

Sequana Medical FIRST LOOK: Additional funding extends runway to YE25

Sequana announced that it has secured additional financing including a €4m convertible, and a facility agreement with GEM up to €20m, as well as amending the terms of the Kreos and PMV loans. The new cash provides funding to YE25, and gives the company breathing room to progress towards US commercialisation of the alfapump expected in 3Q25. We plan to incorporate this new financing in a future model update. BUY reiterated.

2h / 1m 2h / 1m 1 EN

Jacob Mekhael ... (+2)

Jacob Mekhael
Wim Hoste

Morning Notes : SEQUA BB, SOLB BB

: SEQUA BB, SOLB BB

2h / 10m 2h / 10m 1 EN

Wim Hoste

Wim Hoste

Solvay From gold to silver in soda ash

Solvay has lost its top spot in the global soda ash market following the acquisition of Genesis Alkali by WE Soda. Whilst soda ash prices continue to be impacted in 2025 by weak end markets, we still see a case for a gradual market tightening and increasing pricing power in the years ahead. Combined with continued savings deliveries, this translates into an adjusted EBITDA CAGR forecast of 5.5% for the period 2026-2028, after a presumed flat 2025. Solvay is a base chemicals group with a prudent balance sheet approach (net debt/EBITDA 1.5x) and focus on (mild) organic growth which results in a ...

2h / 32m 2h / 32m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Zealand Pharma Completes petrelintide phase 2b enrolment in obesity/overweight

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : ZEAL DC

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Sequana Medical FIRST LOOK: Additional funding extends runway to YE25

Morning Notes : SEQUA BB, SOLB BB

Solvay From gold to silver in soda ash

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe